Advertisement

 

 

Development of targeted adjuvants for HIV-1 vaccines.

Development of targeted adjuvants for HIV-1 vaccines.
Author Information (click to view)

Liu J, Ostrowski M,


Liu J, Ostrowski M, (click to view)

Liu J, Ostrowski M,

Advertisement

AIDS research and therapy 2017 09 1214(1) 43 doi 10.1186/s12981-017-0165-8

Abstract

Finding new adjuvants is an integrated component of the efforts in developing an effective HIV-1 vaccine. Compared with traditional adjuvants, a modern adjuvant in the context of HIV-1 prevention would elicit a durable and potent memory response from B cells, CD8(+) T cells, and NK cells but avoid overstimulation of HIV-1 susceptible CD4(+) T cells, especially at genital and rectal mucosa, the main portals for HIV-1 transmission. We briefly review recent advances in the studies of such potential targeted adjuvants, focusing on three classes of molecules that we study: TNFSF molecules, TLRs agonists, and NODs agonists.

Submit a Comment

Your email address will not be published. Required fields are marked *

15 + 4 =

[ HIDE/SHOW ]